SCHEMBL801762

SCHEMBL801762

CCc1cc(Nc2cnnc(-c3cccc(Cl)c3)n2)n[nH]1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRK6 P43250 10/20 0.41
AURKA O14965 4/20 0.41
PDE4B Q07343 6/20 0.40
PDE4D Q08499 3/20 0.40
IGF1R P08069 3/20 0.40
DAPK3 O43293 1/20 0.40
CHEK2 O96017 1/20 0.40
NTRK1 P04629 1/20 0.40
GRK4 P32298 1/20 0.40
GRK5 P34947 1/20 0.40
PTK2 Q05397 1/20 0.40
GRK1 Q15835 1/20 0.40
GRK7 Q8WTQ7 1/20 0.40
IDO1 P14902 1/20 0.39
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
ITK Q08881 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805555 0.88 ITK (0.40) GRK6AURKAIGF1RNTRK1IDO1
SCHEMBL801690 0.76 PDE4B (0.48) GRK6AURKAPDE4BPDE4DIGF1R
SCHEMBL801771 0.70 RET (0.40) GRK6AURKAIGF1R
SCHEMBL801772 0.70 ITK (0.52) AURKAITK
SCHEMBL14985496 0.70 ALDH1A1 (0.50) IDO1ALDH1A1POLBAPOBEC3G
SCHEMBL4177633 0.68 BRAF (0.52) AURKAITK
SCHEMBL14005700 0.66 AURKA (0.43) AURKAPDE4BITK
SCHEMBL12712065 0.66 BACE1 (0.38) PDE4BIDO1
SCHEMBL3852107 0.66 ITK (0.45) GRK6AURKAIGF1RNTRK1ITK
SCHEMBL4193722 0.65 AURKA (0.47) AURKAPDE4BITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-8524720-B2 Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 US disclosed
US-8524720-B2 Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-7951820-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-31 US disclosed
US-7951820-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-31 US disclosed
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-07 US disclosed
US-7691853-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-06 US disclosed
US-7691853-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-06 US disclosed
US-7473691-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-01-06 US disclosed
US-7390815-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-06-24 US disclosed
US-20070270444-A1 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed
US-20070270444-A1 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, CDK3, GSK3A GRK6 766/4885AURKA 7/4885PDE4B 3723/4885
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 GRK6 576/4885AURKA 8/4885PDE4B 3468/4885
US-20070270444-A1 Pyrazole compounds useful as protein kinase inhibitors GSK3B, CDK3, GSK3A GRK6 766/4885AURKA 7/4885PDE4B 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.